ArticlePostepy dermatologii i alergologii2025
Association of skin microbiome with interleukin-23 in patients with plaque psoriasis.
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Psoriasis is a chronic autoimmune disease influenced by immune dysregulation and microbiome alterations. The IL-23/Th17 axis is central to its pathogenesis, promoting inflammation and keratinocyte hyperproliferation. Skin microbiome dysbiosis has been implicated in disease onset, but its relationship with IL-23 requires further exploration. Aim: This study aimed to investigate variations in the skin microbiome between psoriatic patients and healthy controls, and examine the correlation of IL-23 serum levels and genetic polymorphisms with psoriasis presence and severity. Material and methods: This case-control study included 40 patients with plaque psoriasis and 40 healthy controls. Clinical data, including Psoriasis Area and Severity Index (PASI) scores, were collected. Skin microbiome analysis was performed using culture methods, serum IL-23 levels were measured by ELISA, and genetic analysis of the IL-23 rs2201841 polymorphism was conducted using PCR-RFLP. Results: Psoriasis patients exhibited higher fungal growth (75% vs. 17.5%, Conclusions: Alterations in the skin microbiome and reduced IL-23 levels are associated with psoriasis. These findings suggest fungal infections and IL-23 as potential biomarkers for disease diagnosis and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.